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Recently, Valenti et al. (1) reported clinical and angiographic
outcomes after chronic total occlusion (CTO) revascularization
with drug-eluting stents (DESs). In this retrospective analysis, the
investigators demonstrated 77% procedural success with wire-based
CTO crossing strategies and concluded that although treatment
with DESs in this complex lesion subset is associated with favor-
able angiographic patency, CTO percutaneous coronary interven-
tion (PCI) involving subintimal tracking and luminal re-entry
(STAR) techniques was independently predictive of recurrent
occlusion. Speciﬁcally, among a small cohort of 54 patients,
recanalization was accomplished in 50 of them, yet ﬁnal Throm-
bolysis In Myocardial Infarction ﬂow grade 3 was achieved in only
34 patients (63%). At 1 year, a 57% reocclusion rate (31/54
attempts) was demonstrated, but only one-half of the STAR group
underwent angiographic follow-up. Reduced 3-year event-free
survival was also described in comparison with patients treated
with non-STAR techniques.
We believe that these ﬁndings represent misinterpretation in
what is considered subintimal dissection and re-entry CTO PCI
and may therefore be misleading regarding the advantages of the
current CTO PCI technique. First, the STAR technique is tradi-
tionally used as a bail-out maneuver for distal lumen entry through
creation of extensive subintimal dissection planes, often with the
unintended consequence of side branch loss. As exempliﬁed in this
and previous (2) studies, it is an unfavorable method associated
with low procedural and clinical success. Moreover, the long-term
success of this method is dependent on infrequent achievement of
ﬁnal TIMI ﬂow and preservation of distal vessel runoff that are
instead the objectives of more targeted re-entry techniques. For
these reasons, STAR is uncommonly performed at leading CTO
centers and should not be confused with more limited and
contemporary subintimal dissection and re-entry methods. Indeed,
it is likely that the majority of all successful CTO recanalizationprocedures involve guidewire advancement through the subintimal
vessel architecture, further confounding what deﬁnes subintimal
and nonsubintimal CTO PCI (3).
In summary, a predominantly antegrade wire-based strategy of
CTO-PCI is associated with low success rates. The STAR tech-
nique and related outcomes described by Valenti et al. (1) do not
represent more common (and contemporary) CTO PCI methods
that involve targeted guidewire re-entry. The expected adverse
outcome described in the present study should therefore not
discourage the application of more contemporary methods of
luminal re-entry that facilitate procedural success (4). More detailed
clinical outcomes speciﬁc to these methods will be reported from
the ongoing clinical study (NCT01435031).*David E. Kandzari, MD
J. Aaron Grantham, MD
William Lombardi, MD
Craig Thompson, MD
*Piedmont Heart Institute
Suite 300
275 Collier Road
Atlanta, Georgia 30309
E-mail: david.kandzari@piedmont.org
http://dx.doi.org/10.1016/j.jacc.2013.02.055
Please note: Dr. Kandzari has received research/grant support from Abbott Vascular,
Medtronic, and Boston Scientiﬁc; and consulting honoraria from Medtronic and
Boston Scientiﬁc. Dr. Grantham has received research/grant support from Abbott
Vascular, Medtronic, Asahi, and BridgePoint Medical/Boston Scientiﬁc; and
consulting honoraria from Abbott Vascular, Asahi, BridgePoint Medical/Boston
Scientiﬁc, and Vascular Solutions. Dr. Lombardi has equity in BridgePoint Medical/
Boston Scientiﬁc. Dr. Thompson has equity in BridgePoint Medical/Boston Scien-
tiﬁc; and receives consulting honoraria from Abbott Vascular and Terumo Medical.REFERENCES
1. Valenti R, Vergara R, Migliorini A, et al. Predictors of reocclusion after
successful drug-eluting stent-supported percutaneous coronary inter-
vention of chronic total occlusion. J Am Coll Cardiol 2013;61:545–50.
2. Colombo A, Mikhail GW, Michev I, et al. Treating chronic total
occlusions using subintimal tracking and reentry: the STAR technique.
Cathet Cardiovasc Interv 2005;64:407–11.
3. Muhammad KI, Lombardi WL, Christofferson R, Whitlow PL. Sub-
intimal guidewire tracking during successful percutaneous therapy for
chronic coronary total occlusions: insights from an intravascular ultra-
sound analysis. Cathet Cardiovasc Interv 2012;79:43–8.
4. Whitlow PL, Lombardi WL, Araya M, et al. Initial experience with
a dedicated coronary re-entry device for revascularization of chronic total
occlusions. Cathet Cardiovasc Interv 2012;80:807–13.ReplyWe thank Dr. Kandzari and colleagues for their interest in our
study (1). We do not believe that the STAR technique applied to
coronary vessels may be confused with the other techniques used in
chronic total occlusion (CTO) recanalization. The STAR tech-
nique is a relatively quick and easy technique to gain the distal
lumen of the vessel, but the re-entry into the true lumen of all main
branches may be difﬁcult, and even in these cases, the restoration
of a normal ﬂow is achieved in approximately half of cases (63% in
our study).
As stated in their letter, the STAR technique “is uncommonly
performed at leading CTO centers,” and this was the case at our
